The University of Chicago Header Logo

Connection

Mark J. Ratain to Genetic Variation

This is a "connection" page, showing publications Mark J. Ratain has written about Genetic Variation.
Connection Strength

1.017
  1. Challenges in interpreting the evidence for genetic predictors of ototoxicity. Clin Pharmacol Ther. 2013 Dec; 94(6):631-5.
    View in: PubMed
    Score: 0.291
  2. A survey of the population genetic variation in the human kinome. J Hum Genet. 2009 Aug; 54(8):488-92.
    View in: PubMed
    Score: 0.215
  3. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol. 2006 May 10; 24(14):2151-7.
    View in: PubMed
    Score: 0.172
  4. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics. 2008 Aug; 18(8):683-97.
    View in: PubMed
    Score: 0.050
  5. Global gene expression as a function of germline genetic variation. Hum Mol Genet. 2005 Jun 15; 14(12):1621-9.
    View in: PubMed
    Score: 0.040
  6. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003 Aug; 13(8):517-23.
    View in: PubMed
    Score: 0.035
  7. Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis. Cancer Invest. 2001; 19(1):57-64.
    View in: PubMed
    Score: 0.030
  8. A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. Clin Pharmacol Ther. 2020 06; 107(6):1383-1393.
    View in: PubMed
    Score: 0.028
  9. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. Eur Urol Focus. 2019 05; 5(3):416-424.
    View in: PubMed
    Score: 0.024
  10. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):94-104.
    View in: PubMed
    Score: 0.019
  11. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 2014 Dec; 14(6):564-72.
    View in: PubMed
    Score: 0.019
  12. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet. 2014 Oct 15; 23(20):5558-69.
    View in: PubMed
    Score: 0.019
  13. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.
    View in: PubMed
    Score: 0.018
  14. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul; 23(7):374-81.
    View in: PubMed
    Score: 0.018
  15. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. 2012 Sep 26; 4(153):153ps18.
    View in: PubMed
    Score: 0.017
  16. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov. 2008 07; 7(7):568-74.
    View in: PubMed
    Score: 0.012
  17. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.